Gregory Renza
Stock Analyst at RBC Capital
(2.93)
# 1,581
Out of 4,918 analysts
206
Total ratings
37.37%
Success rate
0.64%
Average return
Main Sectors:
Stocks Rated by Gregory Renza
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Outperform | $31 → $35 | $62.90 | -44.36% | 3 | May 23, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Outperform | $26 | $23.53 | +10.50% | 16 | May 19, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Outperform | $8 | $2.69 | +197.40% | 12 | May 15, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Sector Perform | $5 | $1.43 | +249.65% | 11 | May 14, 2025 | |
| EXEL Exelixis | Reiterates: Outperform | $40 | $37.26 | +7.35% | 10 | May 14, 2025 | |
| ONC BeOne Medicines | Maintains: Outperform | $312 → $311 | $299.01 | +4.01% | 2 | May 8, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $182 → $172 | $115.52 | +48.89% | 14 | May 7, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $35 → $32 | $8.11 | +294.57% | 3 | May 2, 2025 | |
| AMGN Amgen | Maintains: Outperform | $324 → $320 | $296.88 | +7.79% | 17 | May 2, 2025 | |
| CGON CG Oncology | Maintains: Outperform | $66 → $68 | $26.31 | +158.46% | 3 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $15 | $3.68 | +307.61% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $11.64 | +3.09% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $6.08 | +130.26% | 10 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $27 | $11.04 | +144.57% | 11 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $24.26 | +151.44% | 12 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $18 | $22.07 | -18.44% | 11 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $48 | $2.88 | +1,566.67% | 4 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 → $10 | $2.23 | +348.43% | 6 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $7 → $10 | $3.75 | +166.67% | 1 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $47 | $17.41 | +169.96% | 11 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $57 | $35.05 | +62.62% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $4 | $6.83 | -41.43% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $11 → $2 | $5.64 | -64.54% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $34 | $7.96 | +327.14% | 8 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $4.70 | +240.43% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $2,160 → $180 | $7.89 | +2,181.37% | 4 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $100 → $80 | $1.66 | +4,719.28% | 5 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $105 → $30 | $0.73 | +3,998.36% | 3 | Jun 2, 2020 |
Cidara Therapeutics
May 23, 2025
Maintains: Outperform
Price Target: $31 → $35
Current: $62.90
Upside: -44.36%
ACADIA Pharmaceuticals
May 19, 2025
Reiterates: Outperform
Price Target: $26
Current: $23.53
Upside: +10.50%
ADC Therapeutics
May 15, 2025
Reiterates: Outperform
Price Target: $8
Current: $2.69
Upside: +197.40%
Inovio Pharmaceuticals
May 14, 2025
Reiterates: Sector Perform
Price Target: $5
Current: $1.43
Upside: +249.65%
Exelixis
May 14, 2025
Reiterates: Outperform
Price Target: $40
Current: $37.26
Upside: +7.35%
BeOne Medicines
May 8, 2025
Maintains: Outperform
Price Target: $312 → $311
Current: $299.01
Upside: +4.01%
Jazz Pharmaceuticals
May 7, 2025
Maintains: Outperform
Price Target: $182 → $172
Current: $115.52
Upside: +48.89%
Bicycle Therapeutics
May 2, 2025
Maintains: Outperform
Price Target: $35 → $32
Current: $8.11
Upside: +294.57%
Amgen
May 2, 2025
Maintains: Outperform
Price Target: $324 → $320
Current: $296.88
Upside: +7.79%
CG Oncology
Apr 29, 2025
Maintains: Outperform
Price Target: $66 → $68
Current: $26.31
Upside: +158.46%
Mar 27, 2025
Maintains: Outperform
Price Target: $16 → $15
Current: $3.68
Upside: +307.61%
Mar 26, 2025
Reiterates: Outperform
Price Target: $12
Current: $11.64
Upside: +3.09%
Mar 21, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $6.08
Upside: +130.26%
Jan 29, 2025
Maintains: Outperform
Price Target: $26 → $27
Current: $11.04
Upside: +144.57%
Jan 15, 2025
Reiterates: Outperform
Price Target: $61
Current: $24.26
Upside: +151.44%
Jan 14, 2025
Reiterates: Sector Perform
Price Target: $18
Current: $22.07
Upside: -18.44%
Jan 9, 2025
Maintains: Outperform
Price Target: $68 → $48
Current: $2.88
Upside: +1,566.67%
Jan 7, 2025
Reiterates: Outperform
Price Target: $6 → $10
Current: $2.23
Upside: +348.43%
Dec 19, 2024
Upgrades: Outperform
Price Target: $7 → $10
Current: $3.75
Upside: +166.67%
Dec 17, 2024
Maintains: Outperform
Price Target: $44 → $47
Current: $17.41
Upside: +169.96%
Dec 10, 2024
Maintains: Outperform
Price Target: $55 → $57
Current: $35.05
Upside: +62.62%
Nov 14, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $6.83
Upside: -41.43%
Nov 5, 2024
Downgrades: Sector Perform
Price Target: $11 → $2
Current: $5.64
Upside: -64.54%
Sep 26, 2024
Maintains: Outperform
Price Target: $31 → $34
Current: $7.96
Upside: +327.14%
Aug 14, 2024
Reiterates: Outperform
Price Target: $16
Current: $4.70
Upside: +240.43%
Jun 27, 2023
Downgrades: Sector Perform
Price Target: $2,160 → $180
Current: $7.89
Upside: +2,181.37%
Mar 16, 2022
Maintains: Sector Perform
Price Target: $100 → $80
Current: $1.66
Upside: +4,719.28%
Jun 2, 2020
Downgrades: Sector Perform
Price Target: $105 → $30
Current: $0.73
Upside: +3,998.36%